Is Loxoprofen registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 4 valid registrations of Loxoprofen, including ROXONIN 60MG TABLET (60 mg, Tablet, SAR 30.40); ROXONIN TAPE (100 mg, Cutaneous patch, SAR 151.80); ROXONIN TAPE 100 mg Cutaneous Patch (100 mg, Cutaneous patch, SAR 37.95); ROXONIN TAPE 50 mg Cutaneous Patch (50 mg, Cutaneous patch, SAR 34.50).

Active substance

Loxoprofen

SFDA 4

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
ROXONIN 60MG TABLET	60 mg	Tablet · Oral use	20 Blister	SAR 30.40	NCE · OTC	SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO	Valid
ROXONIN TAPE	100 mg	Cutaneous patch · Topical	28 Pouch	SAR 151.80	NCE · OTC	SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO	Valid
ROXONIN TAPE 100 mg Cutaneous Patch	100 mg	Cutaneous patch · Topical	7 Pouch	SAR 37.95	NCE · OTC	SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO	Valid
ROXONIN TAPE 50 mg Cutaneous Patch	50 mg	Cutaneous patch · Topical	7 Pouch	SAR 34.50	NCE · OTC	SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO	Valid

Indications — CHI Daman Drug Formulary

ACUTE PANCREATITIS-PAIN MANAGEMENT; BACTERIAL TONSILLOPHARYNGITIS TREATMENT AND PREVENTION; CHRONIC PANCREATITIS; DENTAL ABSCESS-DENTAL PAIN; ENDOMETRIOSIS; INFECTIOUS MONONUCLEOSIS; LOW BACK PAIN; MUCOSAL ULCERATION-SUPPORTIVE AGENTS; PAIN MANAGEMENT IN CANCER PATIENTS; POSTOPERATIVE PAIN; RENAL AND URETERIC STONES; RHEUMATOID ARITHRITIS; SICKLE CELL DISEASE - PAIN MANAGEMENT

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.